8-K: Akari Therapeutics Prioritizes ADC Platform and Geographic Atrophy Program, Secures $7.6 Million in Financing

Akari Therapeutics announced its second quarter 2024 financial results, a strategic shift to focus on its ADC platform and geographic atrophy program, and secured $7.6 million in financing.

Summary

• Akari Therapeutics reported its financial results for the second quarter of 2024, ending June 30th.
• The company had $4.2 million in cash as of June 30, 2024, compared to $3.8 million at the end of 2023.
• Research and development expenses increased to $3.3 million for the quarter and $5.6 million for the six months, primarily due to manufacturing costs for PAS-nomacopan.
• General and administrative expenses decreased to $2.2 million for the quarter and $4.9 million for the six months due to a reduction in force.
• The company incurred $0.3 million and $1.3 million in merger-related costs for the three and six months respectively, related to the proposed merger with Peak Bio.
• Restructuring costs were $1.6 million for both the three and six month periods, related to the reduction in force.
• Akari reported a net loss of $7.6 million for the quarter and $13.1 million for the six months.
• The company is prioritizing its PAS-nomacopan program for geographic atrophy and Peak Bio's antibody drug conjugate (ADC) platform.
• The company has suspended its HSCT-TMA program as a result of the prioritization.
• Akari received positive feedback from the FDA for PAS-nomacopan in geographic atrophy and plans to file an IND application in 2025.
• A full-scale GMP batch of PAS-nomacopan drug substance has been manufactured, sufficient for IND-enabling studies and initial clinical development.
• The merger with Peak Bio is expected to close in the fourth quarter of 2024.
• The company issued $1 million in unsecured convertible notes to provide operating capital.
• Akari raised $7.6 million in gross proceeds from a private placement of ADSs and warrants.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the FDA feedback and financing, the increased losses and restructuring efforts temper the overall sentiment. The strategic shift and focus on key programs are positive, but the financial challenges are a concern.

Positives

• The company has prioritized its most promising programs, focusing on PAS-nomacopan for geographic atrophy and the ADC platform.
• Positive feedback from the FDA for PAS-nomacopan provides a clear path for clinical development.
• The successful manufacturing of a full-scale GMP batch of PAS-nomacopan drug substance is a significant milestone.
• The company secured $7.6 million in financing, strengthening its financial position.
• The merger with Peak Bio is progressing as planned and expected to close in the fourth quarter.
• The appointment of an interim CEO with an equity-based contract aligns management with shareholder interests.

Negatives

• The company reported a net loss of $7.6 million for the quarter and $13.1 million for the six months.
• Research and development expenses increased significantly due to manufacturing costs.
• The company implemented a reduction-in-force, indicating financial pressures.
• The HSCT-TMA program was suspended, which may be a setback for that area of research.
• The company incurred significant restructuring costs of $1.6 million for both the three and six month periods.

Risks

• The company needs additional capital to continue operations and development programs.
• The merger with Peak Bio may not be completed or may not be successful.
• The company may not be able to successfully develop or commercialize its product candidates.
• There are risks related to competition for the company's product candidates.
• The company faces risks related to intellectual property rights and supply chain interruptions.
• The company is exposed to potential legal proceedings and investigations.
• Changes in governmental laws and regulations could impact the company's business.
• Unexpected increases in costs and expenses could negatively impact the company.
• Epidemics, pandemics, or other public health crises could disrupt the company's operations.

Future Outlook

The company plans to file an IND application for PAS-nomacopan in geographic atrophy in the second half of 2025 and expects the merger with Peak Bio to close in the fourth quarter of 2024. They will continue to explore licensing and partnership opportunities for nomacopan and PAS-nomacopan.

Management Comments

• Interim CEO, Dr. Samir R. Patel, stated that the company continues to make progress on multiple fronts and is pleased with the progress of the PAS-nomacopan geographic atrophy development program.
• Dr. Patel also mentioned that the merger with Peak Bio is progressing and remains on track for a fourth quarter closing.

Industry Context

The announcement reflects a trend in the biotech industry towards prioritizing key programs and streamlining operations to conserve resources. The focus on ADC technology and geographic atrophy aligns with areas of high unmet medical need and significant market potential. The merger with Peak Bio is a strategic move to combine complementary assets and expertise.

Comparison to Industry Standards

• The increase in R&D expenses is typical for a biotech company advancing a clinical program, particularly with manufacturing costs for a new drug substance.
• The reduction in G&A expenses through a reduction-in-force is a common cost-cutting measure in the biotech industry, especially for companies facing financial constraints.
• The net loss is significant, but not uncommon for a development-stage biotech company. Companies like Alnylam Pharmaceuticals and BioMarin Pharmaceutical have also reported significant losses while investing in R&D.
• The $7.6 million financing is relatively small compared to larger biotech financings, but it is a positive step for a company of Akari's size and stage.
• The focus on geographic atrophy is a strategic move, as companies like Apellis Pharmaceuticals and Iveric Bio have seen success in this area, indicating a strong market opportunity.

Management Changes

Related Party Transactions

• The company issued unsecured convertible, short-term promissory notes to Dr. Patel and Ray Prudo, M.D., the Company's Chairman of the Board, each in the amount of $500,000.
• Dr. Patel and Dr. Prudo participated in the private placement of ADSs and warrants.

Stakeholder Impact

• Shareholders will be impacted by the strategic shift, the merger, and the financial results.
• Employees were impacted by the reduction-in-force.
• Customers and patients may benefit from the focus on PAS-nomacopan and the ADC platform.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• The company plans to file an IND application for PAS-nomacopan in geographic atrophy in the second half of 2025.
• The merger with Peak Bio is expected to close in the fourth quarter of 2024.
• The company will continue to explore licensing and partnership opportunities for nomacopan and PAS-nomacopan.

Key Dates

Keywords

Akari Therapeutics, PAS-nomacopan, Geographic Atrophy, ADC Platform, Merger, Peak Bio, Financial Results, FDA, Clinical Development, Biotechnology, Financing, Interim CEO, Restructuring